Oral phenylephrine was shown to be ineffective for treating nasal congestion over a year go. This week, the FDA took the ...

The Galaxy Watch is the most mainstream of Samsung's ranges and is designed to compete directly with the Apple Watch. The ...

The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold medications. Here's what you need to know.

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...

Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

Inspire Medical ( (INSP) ) has released its Q3 earnings. Here is a breakdown of the information Inspire Medical presented to its investors.

The technology company has filed a patent for an innovative "smart pillow" aimed at treating obstructive sleep apnea (OSA). If snoring noises are detected, air chambers change the position of the ...

Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President ...

Inspire Medical Systems topped Q3 expectations, signaling continued market strength and innovation.

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...